was FDA is now the companies take on the decision

S Schecter schecters at gmail.com
Fri Dec 15 13:22:34 GMT 2006

• Previous message: FDA Panel Votes Against Blood-Substitute Study
• Next message: On the subject of teaching disaster prep
• Messages sorted by: [ date ] [ thread ] [ subject ] [ author ]

---

http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=bpur&script=419&layout=0&item_id=942537

Snip..."Although the committee advised against RESUS moving forward, we view
its comments today as constructive criticism and generally supportive of the
product's development for the emergency pre-hospital treatment of trauma
patients," said Biopure Chairman and CEO Zafirelis G. Zafirelis."...snip

---

• Previous message: FDA Panel Votes Against Blood-Substitute Study
• Next message: On the subject of teaching disaster prep
• Messages sorted by: [ date ] [ thread ] [ subject ] [ author ]

---

More information about the trauma-list mailing list